STAT+: BridgeBio heart drug succeeds in pivotal study

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also reduced the risk of death by 25% compared to a placebo.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: BridgeBio heart drug succeeds in pivotal study »